Influencing Next-Generation Oncologic Outcomes Through Rapid Integration of Functional Precision Medicine (NOORI): A Feasibility Study of SmartMatch in Rare Gynecologic Cancers
Part of paid clinical trials in Seattle, Washington.
- Sponsor
- Fred Hutchinson Cancer Center
- Study ID
- NCT07731880
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Malignant Female Reproductive System Neoplasm
- Metastatic Malignant Female Reproductive System Neoplasm
- Unresectable Malignant Female Reproductive System Neoplasm
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
This study is being done to determine how easy it is to use standard of care (SOC) surgical resections or biopsy for SmartMatch analysis to determine treatment options in advanced gynecological malignancies.
Key Dates
- First listed
- Jul 28, 2026
- Start date
- Sep 30, 2026
- Status verified
- Jul 2026
- Primary completion
- Jul 31, 2029
- Completion
- Jul 31, 2029
Study Design
- Enrollment
- 30 participants (estimated)
Arms
- Arm: Observational - SmartMatch laboratory analysisPatients undergo tissue sample collection obtained from standard of care surgical resection or biopsy for SmartMatch laboratory analysis and have their medical records reviewed on study.
Primary Outcome Measure
Proportion of participants for whom SmartMatch generates at least one actionable treatment recommendation that is presented at the PMTB within 4 weeks (≤ 28 days) of fresh tissue acquisition [ Time Frame: From enrollment up to 36 months ]
Central Contacts
- Kalyan Banda, MD206-606-2222
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | Kalyan Banda, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Seattle, WA
Related Studies
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPHASE2 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)PHASE2 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic CancersPHASE1 · Recruiting · M.D. Anderson Cancer Center · Baltimore, Maryland
- Cancer Genetic Testing in Ethnic PopulationsRecruiting · Mayo Clinic · Scottsdale, Arizona